Tiziana Life Sciences (TLSA) Total Non-Current Liabilities (2019 - 2025)
Tiziana Life Sciences (TLSA) posted quarterly Total Non-Current Liabilities of $7.4 million for Q2 2025, down 18.82% year-over-year from $9.1 million in Q2 2024, and up 0.71% quarter-over-quarter from $7.3 million in Q4 2024.
Tiziana Life Sciences (TLSA) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends
Tiziana Life Sciences' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $7.4 million for Q2 2025.
- In Q2 2025, Total Non-Current Liabilities fell 18.82% year-over-year to $7.4 million; the TTM figure through Jun 2025 stood at $7.4 million (down 18.82% YoY), while the FY2024 annual figure was $7.3 million, up 10.58% from the prior year.
- Total Non-Current Liabilities for Q2 2025 stood at $7.4 million, up from $7.3 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $9.2 million in Q2 2021, with the low at $4.1 million in Q2 2023.
- The 5-year median for Total Non-Current Liabilities is $7.3 million (2024), against an average of $7.0 million.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities tumbled 42.68% in 2022, then surged 121.06% in 2024.
- Tiziana Life Sciences' Total Non-Current Liabilities stood at $7.5 million in 2021, then declined by 13.2% to $6.5 million in 2022, then increased by 1.42% to $6.6 million in 2023, then climbed by 10.58% to $7.3 million in 2024, then rose by 0.71% to $7.4 million in 2025.
- Business Quant data shows TLSA's Total Non-Current Liabilities at $7.4 million in Q2 2025, $7.3 million in Q4 2024, and $9.1 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 9.32 Bn |
| 10 | Tiziana Life Sciences | 132.48 Mn | 128.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 7.39 Mn |
| Dec 31, 2024 | 7.34 Mn |
| Jun 30, 2024 | 9.10 Mn |
| Dec 31, 2023 | 6.63 Mn |
| Jun 30, 2023 | 4.12 Mn |
| Dec 31, 2022 | 6.54 Mn |
| Jun 30, 2022 | 5.27 Mn |
| Dec 31, 2021 | 7.54 Mn |
| Jun 30, 2021 | 9.19 Mn |
| Dec 31, 2020 | 7.92 Mn |
| Dec 31, 2019 | 7.62 Mn |